Chemokines in the pathogenesis of vascular disease

Circulation Research

Volumn 95, Issue 9, 2004, Pages 858-866

  Charo, Israel F ^a,b   Taubman, Mark B ^c,d  

^a GLADSTONE INSTITUTE OF CARDIOVASCULAR DISEASE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Atherosclerosis; CCR2; Chemokine; Monocyte chemoattractant protein 1; Vascular

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR CCR2; G PROTEIN COUPLED RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN INHIBITOR; RECEPTOR BLOCKING AGENT; THROMBIN; THROMBOPLASTIN;

ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; ATHEROSCLEROTIC PLAQUE RUPTURE; BLOOD VESSEL INJURY; CHEMOTAXIS; GENE EXPRESSION; HUMAN; INFLAMMATION; LEUKOCYTE MIGRATION; LYMPHOCYTE MIGRATION; MONOCYTE; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RUPTURE; THROMBOGENESIS; THROMBOSIS; VASCULAR DISEASE;

ANIMALS; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; CHEMOKINE CCL2; CHEMOKINES; CHEMOTAXIS, LEUKOCYTE; ENDOTHELIUM, VASCULAR; FOAM CELLS; HUMANS; HYPERPLASIA; MICE; MICE, KNOCKOUT; NEOVASCULARIZATION, PHYSIOLOGIC; RABBITS; RATS; RECEPTORS, CHEMOKINE; SUS SCROFA; THROMBIN; THROMBOPLASTIN; TUNICA INTIMA; VASCULAR DISEASES; VASCULITIS;

EID: 7244242357     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000146672.10582.17     Document Type: Review

References (95)

1. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
2. Schober A, Bernhagen J, Thiele M, Zeiffer U, Knarren S, Roller M, Bucala R, Weber C. Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice. Circulation. 2004;109:380-385.
3. Libby P, Ridker PM. Inflammation and atherosclerosis: Role of C-reactive protein in risk assessment. Am J Med. 2004;116:9S-16S.
4. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Airaksinen KEJ, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang I-K, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W, Jr., Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT. From vulnerable plaque to vulnerable patient: A call for new definitions and risk assessment strategies: Part II. Circulation. 2003;108:1772-1778.
5. Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol. 2001;2: 108-115.
6. Rot A, von Andrian UH. Chemokines in innate and adaptive host defense: Basic chemokinese grammar for immune cells. Annu Rev Immunol. 2004; 22:891-928.
7. Stokke T, Collins C, Kuo W-L, Kowbel D, Shadravan F, Tanner M, Kallioniemi A, Kallioniemi O-P, Pinkel D, Deaven L, Gray JW. A physical map of chromosome 20 established using fluorescence in situ hybridization and digital image analysis. Genomics. 1995;26:134-137.
8. Huo Y, Weber C, Forlow SB, Sperandio M, Thatte J, Mack M, Jung S, Littman DR, Ley K. The chemokine KC, but not monocyte chemoattractant protein-1, triggers monocyte arrest on early atherosclerotic endothelium. J Clin Invest. 2001;108:1307-1314.
9. Gerszten RE, Garcia-Zepeda EA, Lim Y-C, Yoshida M, Ding HA, Gimbrone MA, Jr., Luster AD, Luscinskas FW, Rosenzweig A. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature. 1999;398:718-723.
10. Gerszten RE, Lim Y-C, Ding HT, Snapp K, Kansas G, Dichek DA, Cabanas C, Sánchez-Madrid F, Gimbrone MA, Jr, Rosenzweig A, Luscinskas FW, Adhesion of monocytes to vascular cell adhesion molecule-1-transduced human endothelial cells. Implications for atherogenesis. Circ Res. 1998;82:871-878.
11. 3C motif. Nature. 1997;385:640-644.
12. Pan Y, Lloyd C, Zhou H, Dolich S, Deeds J, Gonzalo J-A, Vath J, Gosselin M, Ma J, Dussault B, Woolf E, Alperin G, Culpepper J, Gutierrez-Ramos JC, Gearing D. Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature. 1997;387:611-617.
13. 3CR1-expressing cells is independent of G-protein activation. J Biol Chem. 1999;274:10053-10058.
14. 3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med. 1998;188:1413-1419.
15. Tsou C-L, Haskell CA, Charo IF. Tumor necrosis factor-α-converting enzyme mediates the inducible cleavage of fractalkine. J Biol Chem. 2001;276:44622-44626.
16. Matloubian M, David A, Engel S, Ryan JE, Cyster JG. A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat Immunol. 2000;1:298-304.
17. Shimaoka T, Kume N, Minami M, Hayashida K, Kataoka H, Kita T, Yonehara S. Molecular cloning of a novel scavenger receptor for oxidized low density lipoprotein, SR-PSOX, on macrophages. J Biol Chem. 2000; 275:40663-40666.
18. Xu J, Wang F, Van Keymeulen A, Herzmark P, Straight A, Kelly K, Takuwa Y, Sugimoto N, Mitchison T, Bourne HR. Divergent signals and cytoskeletal assemblies regulate self-organizing polarity in neutrophils. Cell. 2003;114:201-214.
19. 3- and Rho GTPase-mediated positive feedback loop regulates neutrophil polarity. Nat Cell Biol. 2002;4:509-512.
20. Gerrity RG, Naito HK. Ultrastructural identification of monocyte-derived foam cells in fatty streak lesions. Artery. 1980;8:208-214.
21. Faggiotto A, Ross R, Harker L. Studies of hypercholesterolemia in the nonhuman primate. I. Changes that lead to fatty streak formation. Arteriosclerosis. 1984;4:323-340.
22. Nelken NA, Coughlin SR, Gordon D, Wilcox JN. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest. 1991; 88:1121-1127.
23. Yu X, Dluz S, Graves DT, Zhang L, Antoniades HN, Hollander W, Prusty S, Valente AJ, Schwartz CJ, Sonenshein GE. Elevated expression of monocyte chemoattractant protein 1 by vascular smooth muscle cells in hypercholesterolemic primates. Proc Natl Acad Sci U S A. 1992;89: 6953-6957.
24. Steinberg D. Lewis A. Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis. Circulation. 1997;95:1062-1071.
25. Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ, Fogelman AM. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A. 1990;87: 5134-5138.
26. Grewal IS, Rutledge BJ, Fiorillo JA, Gu L, Gladue RP, Flavell RA, Rollins BJ. Transgenic monocyte chemoattractant protein-1 (MCP-1) in pancreatic islets produces monocyte-rich insulitis without diabetes. Abrogation by a second transgene expressing systemic MCP-1. J Immunol. 1997;159:401-408.
27. Aiello RJ, Bourassa P-AK, Lindsey S, Weng W, Natoli E, Rollins BJ, Milos PM. Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 1999;19:1518-1525.
28. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, Rollins BJ. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell. 1998;2: 275-281.
29. Gosling J, Slaymaker S, Gu L, Tseng S, Zlot CH, Young SG, Rollins BJ, Charo IF. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest. 1999;103: 773-778.
30. -/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998;394:894-897.
31. Dawson TC, Kuziel WA, Osahar TA, Maeda N. Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis. 1999;143:205-211.
32. Kuziel WA, Dawson TC, Quinones M, Garavito E, Chenaux G, Ahuja SS, Reddick RL, Maeda N. CCR5 deficiency is not protective in the early stages of atherogenesis in apoE knockout mice. Atherosclerosis. 2003; 167:25-32.
33. Boring L, Gosling J, Chensue SW, Kunkel SL, Farese RV, Jr., Broxmeyer HE, Charo IF. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest. 1997;100:2552-2561.
34. Lu B, Rutledge BJ, Gu L, Fiorillo J, Lukacs NW, Kunkel SL, North R, Gerard C, Rollins BJ. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J Exp Med. 1998;187:601-608.
35. H2 polarization by the chemokine monocyte chemoattractant protein-1. Nature. 2000;404:407-411.
36. Sarafi MN, Garcia-Zepeda EA, MacLean JA, Charo IF, Luster AD. Murine monocyte chemoattractant protein (MCP)-5: A novel CC chemokine that is a structural and functional homologue of human MCP-1. J Exp Med. 1997;185:99-109.
37. Kurihara T, Bravo R. Cloning and functional expression of mCCR2, a murine receptor for the C-C chemokines JE and FIC. J Biol Chem. 1996;271:11603-11607.
38. Veillard NR, Kwak B, Pelli G, Mulhaupt F, James RW, Proudfoot AEI, Mach F. Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res. 2004;94:253-261.
39. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347: 1557-1565.
40. Reidy MA, Fingerle J, Lindner V. Factors controlling the development of arterial lesions after injury. Circulation. 1992;86: III-43-III-46.
41. Schwartz SM, Heimark RL, Majesky MW. Developmental mechanisms underlying pathology of arteries. Physiol Rev. 1990;70:1177-1209.
42. Ross R. Growth regulatory mechanisms and formation of the lesions of atherosclerosis. Ann NY Acad Sci. 1995;748:1-4.
43. Furukawa Y, Matsumori A, Ohashi N, Shioi T, Ono K, Harada A, Matsushima K, Sasayama S. Anti-monocyte chemoattraciant protein-1/ monocyte chemotactic and activating factor antibody inhibits neointimal hyperplasia in injured rat carotid arteries. Circ Res. 1999;84:306-314.
44. Taubman MB, Rollins BJ, Poon M, Marmur J, Green RS, Berk BC, Nadal-Ginard B. JE mRNA accumulates rapidly in aortic injury and in platelet-derived growth factor-stimulated vascular smooth muscle cells. Circ Res. 1992;70:314-325.
45. Wysocki SJ, Zheng MH, Smith A, Lamawansa MD, Iacopetta BJ, Robertson TA, Papadimitriou JM, House AK, Norman PE. Monocyte chemoattractant protein-1 gene expression in injured pig artery coincides with early appearance of infiltrating monocyte/macrophages. J Cell Biochem. 1996;62:303-313.
46. Clowes AW, Clowes MM, Fingerle J, Reidy MA. Regulation of smooth muscle cell growth in injured artery. J Cardiovasc Pharmacol. 1989; 14(Suppl 6):S12-S15.
47. Roque M, Fallon JT, Badimon JJ, Zhang WX, Taubman MB, Reis ED. Mouse model of femoral artery denudation injury associated with the rapid accumulation of adhesion molecules on the luminal surface and recruitment of neutrophils. Arterioscler Thromb Vasc Biol. 2000;20: 335-342.
48. Egashira K, Zhao Q, Kataoka C, Ohtani K, Usui M, Charo IF, Nishida K-I, Inoue S, Katoh M, Ichiki T, Takeshita A. Importance of monocyte chemoattractant protein-1 pathway in neointimal hyperplasia after periarterial injury in mice and monkeys. Circ Res. 2002;90:1167-1172.
49. Horvath C, Welt FGP, Nedelman M, Rao P, Rogers C. Targeting CCR2 or CD18 inhibits experimental in-stent restenosis in primates. Inhibitory potential depends on type of injury and leukocytes targeted. Circ Res. 2002;90:488-494.
50. Roque M, Kim WJH, Gazdoin M, Malik A, Reis ED, Fallon JT, Badimon JJ, Charo IF, Taubman MB. CCR2 deficiency decreases intimal hyperplasia after arterial injury. Arterioscler Thromb Vasc Biol. 2002;22: 554-559.
51. Kim WJH, Chereshnev I, Gazdoiu M, Fallon JT, Rollins BJ, Taubman MB. MCP-1 deficiency is associated with reduced intimal hyperplasia after arterial injury. Biochem Biophys Res Commun. 2003;310:936-942.
52. -/- aortic smooth muscle cells. J Leukoc Biol. 2004;75:1079-1085.
53. Schecter AD, Rollins BJ, Zhang YJ, Charo IF, Fallon JT, Rossikhina M, Giesen PLA, Nemerson Y, Taubman MB. Tissue factor is induced by monocyte chemoattractant protein-1 in human aortic smooth muscle and THP-1 cells. J Biol Chem. 1997;272:28568-28573.
54. Ikeda U, Ikeda M, Seino Y, Takahashi M, Kasahara T, Kano S, Shimada K. Expression of intercellular adhesion molecule-1 on rat vascular smooth muscle cells by pro-inflammatory cytokines. Atherosclerosis. 1993;104: 61-68.
55. Viedt C, Vògel J, Athanasiou T, Shen W, Orth SR, Kübler W, Kreuzer J. Monocyte chemoattractant protein-1 induces proliferation and interleukin-6 production in human smooth muscle cells by differential activation of nuclear factor-κB and activator protein-1. Arterioscler Thromb Vasc Biol. 2002;22:914-920.
56. Watanabe T, Pakala R, Katagiri T, Benedict CR. Monocyte chemotactic protein 1 amplifies serotonin-induced vascular smooth muscle cell proliferation. J Vasc Res. 2001;38:341-349.
57. Prossnitz ER, Quehenberger O, Cochrane CG, Ye RD. The role of the third intracellular loop of the neutrophil N-formyl peptide receptor in G protein coupling. Biochem J. 1993;294:581-587.
58. Ikeda U, Okada K, Ishikawa S, Saito T, Kasahara T, Shimada K. Monocyte chemoattractant protein 1 inhibits growth of rat vascular smooth muscle cells. Am J Physiol. 1995;268:H1021-H1026.
59. Kodali RB, Kim WJH, Galaria II, Miller C, Schecter AD, Lira SA, Taubman MB. CCL11 (eotaxin) induces CCR3-dependent smooth muscle cell migration. Arterioscler Thromb Vasc Biol. 2004;24:1211-1216.
60. Schecter AD, Calderon TM, Berman AB, McManus CM, Fallon JT, Rossikhina M, Zhao W, Christ G, Berman JW, Taubman MB. Human vascular smooth muscle cells possess functional CCR5. J Biol Chem. 2000;275:5466-5471.
61. Haque NS, Fallon JT, Pan JJ, Taubman MB, Harpel PC. Chemokine receptor-8 (CCR8) mediates human vascular smooth muscle cell chemotaxis and metalloproteinase-2 secretion. Blood. 2004;103:1296-1304.
62. Schober A, Manka D, von Hundelshausen P, Huo Y, Hanrath P, Sarembock IJ, Ley K, Weber C. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation. 2002;106:1523-1529.
63. Schober A, Knarren S, Lietz M, Lin EA, Weber C. Crucial role of stromal cell-derived factor-1α in neointima formation after vascular injury in apolipoprotein E-deficient mice. Circulation. 2003;108:2491-2497.
64. Liu L, Lalani A, Dai E, Seet B, Macauley C, Singh R, Fan L, McFadden G, Lucas A. The viral anti-inflammatory chemokine-binding protein M-T7 reduces intimal hyperplasia after vascular injury. J Clin Invest. 2000;105:1613-1621.
65. Pyo R, Jensen KK, Wiekowski MT, Manfra D, Alcami A, Taubman MB, Lira SA. Inhibition of intimal hyperplasia in transgenic mice conditionally expressing the chemokine-binding protein M3. Am J Pathol. 2004;164:2289-2297.
66. Helisch A, Schaper W. Arteriogenesis. The development and growth of collateral arteries. Microcirculation. 2003;10:83-97.
67. van Royen N, Hoefer I, Buschmann I, Kostin S, Voskuil M, Bode C, Schaper W, Piek JJ. Effects of local MCP-1 protein therapy on the development of the collateral circulation and atherosclerosis in Watanabe hyperlipidemic rabbits. Cardiovasc Res. 2003;57:178-185.
68. van Royen N, Hoefer I, Böttinger M, Hua J, Grundmann S, Voskuil M, Bode C, Schaper W, Buschmann I, Piek JJ. Local monocyte chemoattractant protein-1 therapy increases collateral artery formation in apolipoprotein E-deficient mice but induces systemic monocytic CD11b expression, neointimal formation, and plaque progression. Circ Res. 2003;92:218-225.
69. Heil M, Ziegelhoeffer T, Wagner S, Fernández B, Helisch A, Martin S, Tribulova S, Kuziel WA, Bachmann G, Schaper W. Collateral artery growth (arteriogenesis) after experimental arterial occlusion is impaired in mice lacking CC-chemokine receptor-2. Circ Res. 2004;94:671-677.
70. Han KH, Chang MK, Boullier A, Green SR, Li A, Glass CK, Quehenberger O. Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor γ. J Clin Invest. 2000;106:793-802.
71. Han KH, Han KO, Green SR, Quehenberger O. Expression of the monocyte chemoattractant protein-1 receptor CCR2 is increased in hypercholesterolemia: Differential effects of plasma lipoproteins on monocyte function. J Lipid Res. 1999;40:1053-1063.
72. Lee B, Doranz BJ, Rana S, Yi Y, Mellado M, Frade JMR, Martinez-A C, O'Brien SJ, Dean M, Collman RG, Doms RW. Influence of the CCR2-V64I polymorphism on human immunodeficiency virus type 1 coreceptor activity and on chemokine receptor function of CCR2b, CCR3, CCR5, and CXCR4. J Virol. 1998;72:7450-7458.
73. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, Lomb DA, Goedert JJ, O'Brien TR, Jacobson LP, Kaslow R, Buchbinder S, Vittinghoff E, Vlahov D, Hoots K, Hilgartner MW, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study, O'Brien SJ. Contrasting genetic influence of CCK2 and CCR5 variants on HIV-1 infection and disease progression. Science. 1997;277:959-965.
74. Hizawa N, Yamaguchi E, Furuya K, Jinushi E, Ito A, Kawakami Y. The role of the C-C chemokine receptor 2 gene polymorphism V641 (CCR2-64I) in sarcoidosis in a Japanese population. Am J Respir Crit Care Med. 1999;159:2021-2023.
75. Abdi R, Tran TBH, Sahagun-Ruiz A, Murphy PM, Brenner BM, Milford EL, McDermott DH. Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. J Am Soc Nephrol. 2002;13: 754-758.
76. Valdes AM, Wolfe ML, O'Brien EJ, Spurr NK, Gefter W, Rut A, Groot PHE, Rader DJ. Val64Ile polymorphism in the C-C chemokine receptor 2 is associated with reduced coronary artery calcification. Arterioscler Thromb Vasc Biol. 2002;22:1924-1928.
77. Ortlepp JR, Vesper K, Mevissen V, Schmitz F, Janssens U, Franke A, Hanrath P, Weber C, Zerres K, Hoffmann R. Chemokine recptor (CCR2) genotype is associated with myocardial infarction and heart failure in patients under 65 years of age. J Mol Med. 2003;81:363-367.
78. de Lemos JA, Morrow DA, Sabatine MS, Murphy SA, Gibson CM, Antman EM, McCabe CH, Cannon CP, Braunwald E. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation. 2003;107:690-695.
79. Boisvert WA, Santiago R, Curtiss LK, Terkeltaub RA. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest. 1998;101:353-363.
80. Geissman F, Jung S, Littman DR. Blood monocytes consists of two principal subsets with distinct migratory properties. Immunity. 2003;19: 71-82.
81. + monocytes. J Exp Med. 2003;197:1701-1707.
82. Umehara H, Goda S, Imai T, Nagano Y, Minami Y, Tanaka Y, Okazaki T, Bloom ET, Domae N. Fractalkine, a CX3C-chemokine, functions predominantly as an adhesion molecule in monocytic cell line THP-1. Immunol Cell Biol. 2001;79:298-302.
83. Kerfoot SM, Lord SE, Bell RB, Gill V, Robbins SM, Kubes P. Human fractalkine mediates leukocyte adhesion but not capture under physiological shear conditions; a mechanism for selective monocyte recruitment. Eur J Immunol. 2003;33:729-739.
84. Greaves DR, Häkkinen T, Lucas AD, Liddiard K, Jones E, Quinn CM, Senaratne J, Green FR, Tyson K, Boyle J, Shanahan C, Weissberg PL, Gordon S, Ylä-Hertualla S. Linked chromosome 16q13 chemokines, macrophage-derived chemokine, fractalkine, and thymus- and activation-regulated chemokine, are expressed in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2001;21:923-929.
85. McDermott DH, Halcox JPJ, Schenke WH, Waclawiw MA, Merrell MN, Epstein N, Quyyumi AA, Murphy PM. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res. 2001;89:401-407.
86. Moatti D, Faure S, Fumeron F, Amara MEW, Seknadji P, McDermott DH, Debré P, Aumont MC, Murphy PM, de Prost D, Combadière C. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood. 2001;97:1925-1928.
87. 3CR1 reveals a role for fractalkine in cardiac allograft rejection. J Clin Invest. 2001;108:679-688.
88. -/- mice reveals a role for fractalkine in atherogenesis. J Clin Invest. 2003; 111:333-340.
89. Combadière C, Potteaux S, Gao J-L, Esposito B, Casanova S, Lee EJ, Debré P, Tedgui A, Murphy PM, Mallat Z. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation. 2003;107:1009-1016.
90. McDermott DH, Fong AM, Yang Q, Sechler JM, Cupples LA, Merrell MN, Wilson PWF, D'Agostino RB, O'Donnell CJ, Patel DD, Murphy PM. Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J Clin Invest. 2003;111:1241-1250.
91. Wilbanks A, Zondlo SC, Murphy K, Mak S, Soler D, Langdon P, Andrew DP, Wu L, Briskin M. Expression cloning of the STRL33/BONZO/ TYMSTR ligand reveals elements of CC, CXC, and CX3C chemokines. J Immunol 2001;166:5145-5154.
92. Shimaoka T, Nakayama T, Fukumoto N, Kume N, Takahashi S, Yamaguchi J, Minami M, Hayashida K, Kita T, Ohsumi J, Yoshie O, Yonehara S. Cell surface-anchored SR-PSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6-expressing cells. J Leukoc Biol. 2004;75:267-274.
93. Gough PJ, Garton KJ, Wille PT, Rychlewski M, Dempsey PJ, Raines EW. A disintegrin and metalloproteinase 10-mediated cleavage and shedding regulates the cell surface expression of CXC chemokine ligand 16. J Immunol. 2004;172:3678-3685.
94. Wuttge DM, Zhou X, Sheikine Y, Wågsäter D, Stemme V, Hedin U, Stemme S, Hansson GK, Sirsjö A. CXCL16/SR-PSOX is an interferon-γ- regulated chemokine and scavenger receptor expressed in atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2004;24:750-755.
95. Nakayama T, Hieshima K, Izawa D, Tatsumi Y, Kanamaru A, Yoshie O. Cutting edge: Profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. J Immunol. 2003;170:1136-1140.